FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious κ opioid agonist with unprecedented selectivity

Todd W Vanderah, Claudio D. Schteingart, Jerzy Trojnar, Jean Louis Junien, Josephine Lai, Pierre J M Riviere

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The side effects typically associated with the clinical profiles of opioid μ-receptor agonists have driven continuing efforts to identify novel efficacious analgesics, including agonists acting at opioid K receptors. Unfortunately, the therapeutic potential of κ agonists seems limited by significant central nervous system side effects. κ Opioid agonists, however, exhibit potent peripherally mediated antihyperalgesic and antinociceptive effects, suggesting that a peripherally acting κ agonist may be efficacious in pain control with a more desirable safety profile than that associated with currently available opioids. Here, we report an all D-amino acid tetrapeptide characterized as a novel, highly selective κ opioid receptor agonist. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2) showed selectivity for the human κ opioid receptor of greater than 30,000- and 68,000-fold versus human μ opioid receptor and human δ-opioid receptor receptors, respectively, and efficacious agonist activity using in vitro tissue assays. FE200041 produced local, peripheral antinociception in the hindpaw ipsilateral, but not contralateral, to injection. Antinociceptive effects of FE200041 in the mouse acetic acid writhing assay lasted over 60 min and were antagonized by naloxone and by selective κ, but not μ, opioid receptor antagonists. FE200041 significantly inhibited acetic acid writhing and inhibited formalin-induced flinching in rats. FE200041 did not elicit sedation or motor impairment after systemic administration at a dose 10-fold higher than that needed to achieve antinociception. FE200041 is thus a potent peripherally restricted opioid κ agonist with no demonstrable side effects typical of κ agonists with central nervous system activity and with unprecedented selectivity for the opioid κ receptor. The pharmacology of this compound suggests the possibility of therapeutic application.

Original languageEnglish (US)
Pages (from-to)326-333
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume310
Issue number1
DOIs
StatePublished - Jul 2004

Fingerprint

Opioid Receptors
Opioid Analgesics
Acetic Acid
Central Nervous System
Narcotic Antagonists
Naloxone
phenylalanyl-phenylalanyl-norleucyl-argininamide
Formaldehyde
Analgesics
Pharmacology
Safety
Amino Acids
Pain
Injections
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2) : A peripheral efficacious κ opioid agonist with unprecedented selectivity. / Vanderah, Todd W; Schteingart, Claudio D.; Trojnar, Jerzy; Junien, Jean Louis; Lai, Josephine; Riviere, Pierre J M.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 310, No. 1, 07.2004, p. 326-333.

Research output: Contribution to journalArticle

Vanderah, Todd W ; Schteingart, Claudio D. ; Trojnar, Jerzy ; Junien, Jean Louis ; Lai, Josephine ; Riviere, Pierre J M. / FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2) : A peripheral efficacious κ opioid agonist with unprecedented selectivity. In: Journal of Pharmacology and Experimental Therapeutics. 2004 ; Vol. 310, No. 1. pp. 326-333.
@article{644e016852ef431abbb76bff86a42f13,
title = "FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2): A peripheral efficacious κ opioid agonist with unprecedented selectivity",
abstract = "The side effects typically associated with the clinical profiles of opioid μ-receptor agonists have driven continuing efforts to identify novel efficacious analgesics, including agonists acting at opioid K receptors. Unfortunately, the therapeutic potential of κ agonists seems limited by significant central nervous system side effects. κ Opioid agonists, however, exhibit potent peripherally mediated antihyperalgesic and antinociceptive effects, suggesting that a peripherally acting κ agonist may be efficacious in pain control with a more desirable safety profile than that associated with currently available opioids. Here, we report an all D-amino acid tetrapeptide characterized as a novel, highly selective κ opioid receptor agonist. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2) showed selectivity for the human κ opioid receptor of greater than 30,000- and 68,000-fold versus human μ opioid receptor and human δ-opioid receptor receptors, respectively, and efficacious agonist activity using in vitro tissue assays. FE200041 produced local, peripheral antinociception in the hindpaw ipsilateral, but not contralateral, to injection. Antinociceptive effects of FE200041 in the mouse acetic acid writhing assay lasted over 60 min and were antagonized by naloxone and by selective κ, but not μ, opioid receptor antagonists. FE200041 significantly inhibited acetic acid writhing and inhibited formalin-induced flinching in rats. FE200041 did not elicit sedation or motor impairment after systemic administration at a dose 10-fold higher than that needed to achieve antinociception. FE200041 is thus a potent peripherally restricted opioid κ agonist with no demonstrable side effects typical of κ agonists with central nervous system activity and with unprecedented selectivity for the opioid κ receptor. The pharmacology of this compound suggests the possibility of therapeutic application.",
author = "Vanderah, {Todd W} and Schteingart, {Claudio D.} and Jerzy Trojnar and Junien, {Jean Louis} and Josephine Lai and Riviere, {Pierre J M}",
year = "2004",
month = "7",
doi = "10.1124/jpet.104.065391",
language = "English (US)",
volume = "310",
pages = "326--333",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2)

T2 - A peripheral efficacious κ opioid agonist with unprecedented selectivity

AU - Vanderah, Todd W

AU - Schteingart, Claudio D.

AU - Trojnar, Jerzy

AU - Junien, Jean Louis

AU - Lai, Josephine

AU - Riviere, Pierre J M

PY - 2004/7

Y1 - 2004/7

N2 - The side effects typically associated with the clinical profiles of opioid μ-receptor agonists have driven continuing efforts to identify novel efficacious analgesics, including agonists acting at opioid K receptors. Unfortunately, the therapeutic potential of κ agonists seems limited by significant central nervous system side effects. κ Opioid agonists, however, exhibit potent peripherally mediated antihyperalgesic and antinociceptive effects, suggesting that a peripherally acting κ agonist may be efficacious in pain control with a more desirable safety profile than that associated with currently available opioids. Here, we report an all D-amino acid tetrapeptide characterized as a novel, highly selective κ opioid receptor agonist. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2) showed selectivity for the human κ opioid receptor of greater than 30,000- and 68,000-fold versus human μ opioid receptor and human δ-opioid receptor receptors, respectively, and efficacious agonist activity using in vitro tissue assays. FE200041 produced local, peripheral antinociception in the hindpaw ipsilateral, but not contralateral, to injection. Antinociceptive effects of FE200041 in the mouse acetic acid writhing assay lasted over 60 min and were antagonized by naloxone and by selective κ, but not μ, opioid receptor antagonists. FE200041 significantly inhibited acetic acid writhing and inhibited formalin-induced flinching in rats. FE200041 did not elicit sedation or motor impairment after systemic administration at a dose 10-fold higher than that needed to achieve antinociception. FE200041 is thus a potent peripherally restricted opioid κ agonist with no demonstrable side effects typical of κ agonists with central nervous system activity and with unprecedented selectivity for the opioid κ receptor. The pharmacology of this compound suggests the possibility of therapeutic application.

AB - The side effects typically associated with the clinical profiles of opioid μ-receptor agonists have driven continuing efforts to identify novel efficacious analgesics, including agonists acting at opioid K receptors. Unfortunately, the therapeutic potential of κ agonists seems limited by significant central nervous system side effects. κ Opioid agonists, however, exhibit potent peripherally mediated antihyperalgesic and antinociceptive effects, suggesting that a peripherally acting κ agonist may be efficacious in pain control with a more desirable safety profile than that associated with currently available opioids. Here, we report an all D-amino acid tetrapeptide characterized as a novel, highly selective κ opioid receptor agonist. FE200041 (D-Phe-D-Phe-D-Nle-D-Arg-NH2) showed selectivity for the human κ opioid receptor of greater than 30,000- and 68,000-fold versus human μ opioid receptor and human δ-opioid receptor receptors, respectively, and efficacious agonist activity using in vitro tissue assays. FE200041 produced local, peripheral antinociception in the hindpaw ipsilateral, but not contralateral, to injection. Antinociceptive effects of FE200041 in the mouse acetic acid writhing assay lasted over 60 min and were antagonized by naloxone and by selective κ, but not μ, opioid receptor antagonists. FE200041 significantly inhibited acetic acid writhing and inhibited formalin-induced flinching in rats. FE200041 did not elicit sedation or motor impairment after systemic administration at a dose 10-fold higher than that needed to achieve antinociception. FE200041 is thus a potent peripherally restricted opioid κ agonist with no demonstrable side effects typical of κ agonists with central nervous system activity and with unprecedented selectivity for the opioid κ receptor. The pharmacology of this compound suggests the possibility of therapeutic application.

UR - http://www.scopus.com/inward/record.url?scp=3042694541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042694541&partnerID=8YFLogxK

U2 - 10.1124/jpet.104.065391

DO - 10.1124/jpet.104.065391

M3 - Article

C2 - 14993260

AN - SCOPUS:3042694541

VL - 310

SP - 326

EP - 333

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -